Solventum (NYSE:SOLV) Price Target Cut to $70.00 by Analysts at Wells Fargo & Company

Key Points

• Wells Fargo cut its price target on Solventum to $70 (from $83) and kept an "equal weight" rating, implying roughly a 2.7% downside from the prior close.
• Analyst coverage is mixed: the consensus is a "Hold" with an average target of $86, while individual ratings range from buy to sell (seven Buys, five Holds, one Sell) and targets roughly span $60–$105.
• Q1 beat — Solventum reported EPS of $1.48 vs. $1.35 expected and revenue of $2.01B vs. $1.97B, and management set FY‑2026 guidance at $6.60 EPS while citing margin momentum and stronger wound‑care demand.

Solventum (NYSE:SOLV - Get Free Report) had its price target dropped by equities research analysts at Wells Fargo & Company from $83.00 to $70.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Wells Fargo & Company's target price points to a potential downside of 2.66% from the company's previous close.

SOLV has been the topic of a number of other reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Solventum in a research note on Tuesday, January 27th. Mizuho set a $100.00 price target on shares of Solventum and gave the stock an "outperform" rating in a research note on Tuesday, January 20th. Stifel Nicolaus lifted their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a "buy" rating in a research note on Wednesday, January 7th. Piper Sandler decreased their price target on shares of Solventum from $98.00 to $92.00 and set an "overweight" rating on the stock in a research note on Friday, April 17th. Finally, Rothschild & Co Redburn began coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a "sell" rating and a $60.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $86.00.

Solventum Price Performance

SOLV traded up $2.87 on Wednesday, reaching $71.91. The company had a trading volume of 201,832 shares, compared to its average volume of 1,204,963. The business has a 50 day simple moving average of $67.91 and a 200 day simple moving average of $74.51. The company has a market cap of $12.47 billion, a price-to-earnings ratio of 8.09, a P/E/G ratio of 1.10 and a beta of 0.59. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. Solventum has a 52-week low of $62.38 and a 52-week high of $88.20.

Solventum (NYSE:SOLV - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. Solventum's quarterly revenue was down 3.0% on a year-over-year basis. During the same period last year, the firm posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts anticipate that Solventum will post 6.5 EPS for the current year.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell acquired 1,475 shares of the company's stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.24% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently added to or reduced their stakes in SOLV. Hilltop National Bank boosted its position in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company's stock valued at $25,000 after purchasing an additional 129 shares in the last quarter. CrossGen Wealth LLC bought a new stake in Solventum during the fourth quarter valued at about $25,000. Measured Wealth Private Client Group LLC bought a new stake in Solventum during the third quarter valued at about $25,000. Clearstead Trust LLC boosted its position in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company's stock valued at $26,000 after purchasing an additional 150 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its position in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company's stock valued at $27,000 after purchasing an additional 163 shares in the last quarter.

Solventum News Summary

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q1 beat — Solventum reported EPS $1.48 vs. consensus $1.35 and revenue $2.01B vs. $1.97B, a stronger than expected result that underpins the move. Solventum Reports First Quarter 2026 Financial Results
• Positive Sentiment: Guidance affirmed at the top end — Management set FY‑2026 EPS guidance at $6.60 (midpoint = top of prior range), signaling confidence in demand, which supports the stock re-rating. Company Earnings and Guidance (MarketBeat)
• Positive Sentiment: Revenue mix and product demand cited — Management flagged stronger wound‑care and sterilization product demand as a driver of higher‑end profit expectations, which supports near‑term organic growth and FCF outlook. Solventum forecasts annual profit at higher end on wound care demand
• Positive Sentiment: Margin momentum highlighted on the call — Management and analysts flagged improving margin trends and cost initiatives that could boost profitability over the year. Solventum Earnings Call Signals Margin Momentum Ahead
• Positive Sentiment: Analyst backing — BTIG reaffirmed a “buy” and set a $89 price target, giving visible upside vs. current levels and supporting investor sentiment. Benzinga: BTIG Reaffirms Buy, $89 PT
• Neutral Sentiment: Earnings call/transcript available — Full call transcript and slides provide detail for investors to assess sustainability of margins and organic growth trends. Solventum Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst consensus mixed — some outlets note a consensus “hold,” and previews flagged margin pressure risk even as MedSurg momentum helps results. Zacks: Q1 Preview
• Negative Sentiment: Top‑line softness in aggregate — Reported revenue was down ~3% year‑over‑year (though organic sales rose), a sign investors will watch sustained revenue recovery. MarketBeat: Q1 Earnings Details
• Negative Sentiment: External concerns remain — some commentary highlights broader industry/technology headwinds (e.g., AI-related market worries) that could test the turnaround narrative if they impact procedure volumes or capital spending. Investing.com: AI Concerns Test Turnaround

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.